U.S. Markets open in 1 hr 42 mins

Alexion Pharmaceuticals’ Operational Performance

Kenneth Smith
Alexion Pharmaceuticals’ Operational Performance

Alexion Pharmaceuticals’ (ALXN) total operating expenses increased from $602.4 million in the second quarter of 2017 to $1.35 billion in the second quarter of 2018. It generated operating income of $226.7 million in the second quarter of 2017. In the second quarter of 2018, it had an operating loss of $400.1 million.